Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C48406
http://purl.obolibrary.org/obo/NCIT_C48406
Preferred Name

Veltuzumab
Definitions
A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in cells that overexpress CD20. CD20 antigen is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in cells that overexpress CD20. CD20 antigen is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes.
prefLabel
Veltuzumab
label
Veltuzumab
PDQ_Closed_Trial_Search_ID
428486
code
C48406
Has_Target
prefixIRI
NCIT:C48406
in_subset
Display_Name
Veltuzumab
Preferred_Name
Veltuzumab
FDA_UNII_Code
BPD4DGQ314
Contributing_Source
CTRP
FDA
Maps_To
Veltuzumab
CAS_Registry
728917-18-8
NCI_Drug_Dictionary_ID
428486
Legacy Concept Name
Monoclonal_Antibody_hA20
type
ALT_DEFINITION
A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. IMMU-106 is a type of monoclonal antibody.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
428486
Accepted_Therapeutic_Use_For
non-Hodgkin's lymphoma
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C2746054
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display